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ABSTRACT The role for nerve blood flow (NBF) vs.
other factors in motor nerve conduction (MNC) slow-
ing in short-term diabetes was assessed by evaluating
a1-adrenoceptor antagonist prazosin on NBF, MNC, as
well as metabolic imbalances and oxidative stress in the
neural tissue. Control and diabetic rats were treated
with or without prazosin (5 mgzkg21zd21 for 3 wk). NBF
was measured by hydrogen clearance. Both endoneu-
rial vascular conductance and MNC velocity were de-
creased in diabetic rats vs. controls, and this decrease
was prevented by prazosin. Free NAD1:NADH ratios in
mitochondrial cristae, matrix, and cytosol assessed by
metabolite indicator method, as well as phosphocre-
atine levels and phosphocreatine/creatine ratios, were
decreased in diabetic rats, and this reduction was
ameliorated by prazosin. Neither diabetes-induced ac-
cumulation of two major glycation agents, glucose and
fructose, as well as sorbitol and total malondialdehyde
plus 4-hydroxyalkenals nor depletion of myo-inositol,
GSH, and taurine or decrease in (Na/K)-ATP-ase ac-
tivity were affected by prazosin. In conclusion, de-
creased NBF, but not metabolic imbalances or oxida-
tive stress in the neural tissue, is a key mechanism of
MNC slowing in short-term diabetes. Further experi-
ments are needed to estimate whether preservation of
NBF is sufficient for prevention of nerve dysfunction
and morphological abnormalities in long-standing dia-
betes or whether the aforementioned metabolic imbal-
ances closely associated with impaired neurotropism
are of greater importance in advanced than in early
diabetic neuropathy.—Obrosova, I. G., Van Huysen,
C., Fathallah, L., Cao, X., Stevens, M. J., Greene, D. A.
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The pathogenesis of peripheral diabetic neuropa-
thy (PDN) remains an area of conceptual disagree-
ment. A number of reports indicate that PDN is a
hypoxic neuropathy and that a decrease in nerve
blood flow (NBF) with resulting endoneurial hyp-
oxia is a key mechanism responsible for nerve con-
duction (NC) slowing in the diabetic nerve (1–4).
This view is supported by studies of different antioxi-
dants (1, 2, 5–7) and metal chelators (8, 9), aldose
reductase inhibitors (3, 10, 11), protein kinase C
inhibitors (12), inhibitor of nitric oxide synthase
(12, 13), potassium channel openers (14), amino-
guanidine (15, 16), and various kinds of vasodilators
(13, 17, 18), all of which demonstrate a perfect
correlation between NBF and NC. Other studies,
however, suggest that blood flow is unchanged (19)
or even increased (20, 21) in the diabetic nerve and
that diabetes-induced NC deficit is independent of
NBF, but due to metabolic (20, 22–25) and other
(26, 27) changes in the neural tissue. Among these
changes, different investigators have implicated ac-
cumulation of sorbitol (28–30), depletion of myo-
inositol (22) and taurine (24), a decrease in (Na/
K)-ATP-ase activity (23, 25, 31–33), NAD-redox
imbalances (20), alterations in fatty acid metabolism
(32, 34) as well as deficits of insulin-like growth
factor (IGF) (35) and nerve growth factor (NGF)
(36) to be associated at least in part with nerve
oxidative injury (36).
Vasodilators represent a valuable tool for address-
ing this controversy. The purpose of the present
study was to assess the role of NBF vs. other factors in
motor (M) NC slowing in short-term diabetes by
evaluating the vasodilator, a1-adrenoceptor antago-
nist prazosin, on diabetes-induced neurovascular dys-
function, motor nerve conduction (MNC), as well as
metabolic imbalances and oxidative stress in the
neural tissue.
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MATERIALS AND METHODS
The experiments were performed in accordance with regula-
tions specified by the National Institutes of Health Principles of
Laboratory Animal Care, 1985 Revised Version, and University of
Michigan Protocol for Animal Studies.
Animals
Male Sprague-Dawley rats (Harlan Sprague-Dawley, Indianap-
olis, Ind.), body weight 250–300 g, were fed a standard rat
chow diet (ICN Biomedical, Cleveland, Ohio) and had access
to water ad libitum. Diabetes was induced by a single intraperi-
toneal (i.p.) injection of streptozotocin (55 mg/kg body
weight) to animals fasted overnight. Blood samples for mea-
surements of glucose were taken from the tail vein 48 h after
the streptozotocin injection and the day before the animals
were killed. The rats with blood glucose of 13.8 mM or more
were considered diabetic. The experimental groups comprised
control and diabetic rats treated with or without a1-adrenocep-
tor antagonist prazosin (5 mg z kg body weight21 z day 21 in the
drinking water). The treatment of diabetic rats was started ;48
h after streptozotocin injection; the duration of the experiment
was 3 wk.
Reagents
Unless otherwise stated, all chemicals were of reagent grade
quality and purchased from Sigma Chemical (St. Louis, Mo.).
Methanol (HPLC grade), perchloric acid, hydrochloric acid,
and sodium hydroxide were purchased from Fisher Scientific
(Pittsburgh, Pa.). Ethyl alcohol (200 proof dehydrated alco-
hol, U.S.P. punctilious) was purchased from Quantum Chem-
ical Co. (Tiscola, Ill.). Dihydroxyacetone phosphate dilithium
salt monohydrate was purchased from Fluka BioChemika
(Buchs, Switzerland). b-D-Glucose, sorbitol, N.F., myo-inositol,
C.P., and D-fructose, U.S.P. were purchased from Pfanstiehl
Laboratories, Inc. (Waukegan, Ill.). Kits for malondialdehyde
and 4-hydroxyalkenals assay were purchased from Oxis Inter-
national (Portland, Oreg.).
Experimental procedure
Our pilot experiments revealed that urethane anesthesia
distorts the profile of peripheral nerve metabolites whereas
rat sedation by a short (;15–20 s) exposure to carbon dioxide
with immediate cervical dislocation preserves reduced metab-
olite and high-energy phosphate levels in the range of those
obtained after decapitation without any narcosis (37). For this
reason, two different sets of animals were used for functional
and metabolic studies. In the first set, the rats were anesthe-
tized by urethane (1–1.2 g/kg, i.p.). Motor nerve conduction
velocity (MNCV) measurements were made before the assess-
ment of NBF on the contralateral nerve. In all measurements,
body temperature was monitored by a rectal probe and
maintained at 37°C with a warming pad. Hind limb skin
temperature was also monitored by a thermistor and main-
tained between 36 and 38°C by radiant heat. In the second
set, the rats were sedated by CO2 in a specially designed
chamber (37) and immediately killed by cervical dislocation.
The femoral segments of the left sciatic nerve from each rat
were rapidly (;30 s) dissected, carefully blotted with fine
filter paper to remove any accompanying blood, and frozen
in liquid nitrogen for subsequent measurements of b-hy-
droxybutyrate, acetoacetate, glutamate, a-ketoglutarate, am-
monia, phosphocreatine, creatine, and ATP. The remaining
part of the left and the right nerve were used for measure-
ments of total malondialdehyde plus 4-hydroxyalkenals, GSH,
sorbitol pathway intermediates, myo-inositol, taurine, and
(Na/K)-ATP-ase activity. The group of prazosin-treated con-
trol rats was set up to estimate whether metabolic effects of
prazosin, when present, were specific for diabetic rats. Bio-
chemical measurements in this group were confined to the
parameters that responded to prazosin treatment in the
diabetic group.
Functional studies
Sciatic endoneurial nutritive NBF
NBF was assessed by microelectrode polarography and hydro-
gen clearance (38). The left carotid artery was cannulated
with polyethylene tubing and patency was maintained with
heparinized saline (50 U/ml normal saline). The catheter was
connected to a transducer and the blood pressure monitored
by a MacLab data acquisition system. A tracheostomy was
performed and the animal artificially respired with O2:N2
(20%:80%) using a small animal ventilator (Harvard Appara-
tus, South Natick, Mass.). The right sciatic nerve was exposed
and gently dissected away from the surrounding tissue. The
skin around the incision was positioned to create a reservoir.
A ground electrode was inserted subcutaneously into the
flank of the rat. Using a micromanipulator, H2-sensitive
platinum electrode (tip diameter 0.2 mm; World Precision
Instruments, Sarasota, Fla.) was inserted into the nerve above
the trifurcation. Mineral oil at 37°C was used to fill the
reservoir and prevent diffusion of gases out of the nerve. The
nerve was polarized with 0.25 V; when a stable baseline was
achieved, the animal received a gas mixture containing 10%
H2 that was continued until the current change stabilized
(10–30 min), when H2 flow was terminated. Current record-
ings were made every 30 s until baseline levels were achieved
(30–60 min). After the experiment, mono- or biexponential
clearance curves were fitted to the data (Graphpad Software,
La Jolla, Calif.). Nutritive NBF was taken as the slow compo-
nent of the curve. An average of two determinations at
different sites was used to determine nutritive NBF.
Sciatic MNCV
The left sciatic nerve was stimulated proximally at the sciatic
notch and distally at the ankle via bipolar electrodes with
supramaximal stimuli (8 V) at 20 Hz. The latencies of the
compound muscle action potentials were recorded via bipo-
lar electrodes from the first interosseous muscle of the hind
paw and measured from the stimulus artifact to the onset of
the negative M-wave deflection. MNCV was calculated by
subtracting the distal latency from the proximal latency; the
result was divided into the distance between the stimulating
and recording electrode.
Metabolic studies
Preparation of perchloric extract
Femoral segments (;20 mg) of the left nerve as well as
segments (;20 mg) of a remaining part of the left nerve or
the right nerve were weighed, homogenized in 1.5 ml of
ice-cold 6% HCIO4, and centrifuged at 4000 g for 10 min.
After centrifugation, the samples were immediately neutral-
ized with 5 M K2CO3 to pH 6–7 and centrifuged again at 4000
g for 5 min to precipitate insoluble KCIO4.
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Measurements of glycolytic and tricarboxylic acid cycle
intermediates, ketone bodies, glutamate, ammonia, phosphocreatine,
creatine, and ATP
The steady-state concentrations of glucose, acetoacetate, b-hy-
droxybutyrate, glutamate, a-ketoglutarate, ammonia, pyru-
vate, lactate, phosphocreatine, creatine, and ATP were as-
sayed in perchloric extracts of femoral segments of the left
sciatic nerve spectrofluorometrically (Perkin-Elmer LS-5B,
Norwalk, Conn.) by enzymatic procedures as described by
Lowry and Passonneau (39). The lower limit for all spectroflu-
orometric procedures in our study including sorbitol, fruc-
tose, myo-inositol, and GSH was 0.1 3 1029 M.
GSH measurements
We modified the method of Hissin and Hilf (40) and mixed
0.1 ml of neutralized nerve perchloric extract with 0.89 ml of
0.02 M EDTA in 1.0 M tris-HCI buffer, pH 8.1. The reaction
was initiated by addition of 0.01 ml of O-phthaldialdehyde
(10 mg-1 ml methanol). Initial and final readings were taken
at l excitation: 345 nm, l emission: 425 nm, slits: 5 and 5. The
differences in initial and final readings were compared with
those in corresponding GSH standards (1–1031029 M) pro-
cessed in the same run.
Measurements of sorbitol pathway intermediates, myo-inositol, and
total MDA plus 4-hydroxyalkenals
Nerve segments (;40 mg) were weighed and homogenized in
1 ml 0.1 M Na-phosphate buffer, pH 6.5. A 100 ml volume of
0.3 M zinc sulfate, followed by an equivalent of barium
hydroxide, was then added to 0.4 ml of the homogenate for
protein precipitation. The samples were centrifuged at 4000 g
for 10 min and 100 ml aliquots of the supernatant were taken
for spectrofluorometric measurements of sorbitol, fructose,
and myo-inositol by enzymatic procedures as described previ-
ously (41, 42). The rest of the homogenate was centrifuged at
3000 g for 5 min. Aliquots (200 ml) of the supernatant were
used for measurements of malondialdehyde (MDA) and total
malondialdehyde plus 4-hydroxyalkenals (4-HA) using kits
LPO-586 from Oxis International (Portland, Oreg.). The
method is based on the reaction of a chromogenic reagent,
N-methyl-2-phenylindole, with MDA or MDA and 4-HA after
their differential extraction under hydrochloric or methane-
sulfonic acidic conditions at 45°C (43). The absorbance of
chromogenic product was measured at 586 nm using a
spectrophotometer Beckman DU 640 (Fullerton, Calif.) and
was compared with the absorbance in corresponding stan-
dards.
Taurine measurements
Nerve segments (;10 mg) were homogenized in 1 ml of 6%
trichloroacetic acid and centrifuged at 4000 g for 10 min.
Taurine was measured by reverse-phase high-performance
liquid chromatography (Waters, Milford, Mass.) after precol-
umn derivatization with O-phthaldialdehyde (41, 42, 44).
Glutamine, added after ion exchange chromatography, was
used as the internal standard.
Measurements of (Na/K)-ATP-ase activity
Nerve segments (;10 mg) were homogenized on ice in 2 ml
of 0.2 M sucrose plus 0.02 M Tris-HCl pH 7.5 by three 10 s
bursts with a Polytron model PT 10–35 (Brinkman Instru-
ments, Westbury, N.Y.). Aliquots of homogenate were assayed
enzymatically for total and ouabain-insensitive ATPase activity
as described (45). Ouabain-sensitive Na/K-ATPase activity is
defined as the difference in activity before and after the
addition of ouabain and is expressed as mmol ADP formed/g
wet weight per hour.
Calculations of free mitochondrial and cytosolic NAD1:NADH
ratios
According to classical publications of Krebs’ laboratory (46,
47) and other studies (48), direct measurements of NAD,
NADH, NADP, and NADPH do not provide information on
compartmentalization of nicotinamide adenine nucleotides
between cytosol and mitochondria and do not separate free
from protein-bound forms (only free forms determine direc-
tion and free-energy changes of dehydrogenase reactions).
The same studies proposed an alternative approach for
assessment of free NAD(P)1:NAD(P)H ratios in the cyto-
plasm and mitochondria from ratios of the concentrations of
oxidized and reduced metabolites of suitable NAD(P)-linked
dehydrogenase systems. Using this approach, free NAD1:
NADH ratios for mitochondrial cristae, matrix, and cytoplasm
were calculated from the steady-state metabolite concentra-
tions and the equilibrium constants of b-hydroxybutyrate,
glutamate, and lactate dehydrogenase systems as described
(46, 48):
@NAD1#
@NADH]
mit cristae 5
@acetoacetate]
[b-hydroxybutyrate]
3
1
K1
,
where K1 is the equilibrium constant of b-hydroxybutyrate
dehydrogenase.
@NAD1#
@NADH]
mit matrix 5
@a-ketoglutarate] 3 [ammonia]
[glutamate]
3
1
K2
,
where K2 is the equilibrium constant of glutamate dehydro-
genase.
@NAD1#
@NADH]
cytoplasm 5
@pyruvate]
[lactate]
3
1
K3
,
where K3 is the equilibrium constant of lactate dehydroge-
nase.
Statistical analysis
The results are expressed as mean 6 standard deviation. Data
were subjected to equality of variance F test and then to log
transformation, if necessary, before one-way analysis of vari-
ance. Where overall significance (P,0.05) was attained, indi-
vidual between group comparisons were made using the
Student-Newman-Keuls multiple range test. Significance was
defined at P#0.05. When between-group variance differences
could not be normalized by log transformation (data sets for
body weights, plasma glucose, and some metabolic parame-
ters), the data were analyzed by the nonparametric Kruskal-
Wallis one-way analysis of variance, followed by the Fisher’s
PLSD test for multiple comparisons.
RESULTS
The final body weights were lower in diabetic rats
compared with those in control rats (Table 1). The
initial body weights were similar in these two groups.
No significant difference was found between body
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weights in control and diabetic rats treated with
prazosin and the corresponding untreated groups.
Blood glucose concentrations were increased by
540% in diabetic rats compared with those in control
rats. Prazosin treatment had no effect on blood
glucose concentrations in either control or diabetic
rats.
Sciatic NBF, mean systemic blood pressure (BP),
and endoneurial vascular conductance were 52%,
11.5%, and 40% lower in diabetic rats compared
with those in control rats (P,0.01 for NBF and VC
and , 0.05 for BP, Fig. 1). Prazosin treatment of
diabetic rats further decreased BP (P,0.05 vs. the
untreated diabetic group and , 0.01 vs. controls).
For this reason, prazosin’s effect on NBF was modest
(a 36% increase vs. the untreated diabetic group,
P,0.05 vs. untreated diabetic and , 0.01 vs. control
groups) although a decrease in VC, i.e., NBF:BP
ratio, was completely prevented (P,0.01 vs. the
untreated diabetic group).
Sciatic MNCV was decreased by 26% in diabetic
rats compared with controls (P,0.01, Fig. 2). MNCV
was 27% higher in the prazosin-treated diabetic
group compared with the untreated diabetic group
(P,0.01). No statistically significant difference was
found between MNCVs in prazosin-treated diabetic
group and nondiabetic controls.
Concentrations of acetoacetate, b-hydroxybu-
tyrate, glutamate, a-ketoglutarate, ammonia, lactate,
and pyruvate were similar in the sciatic nerves of
control rats treated with and without prazosin (Table
2). Concentrations of acetoacetate and b-hydroxybu-
tyrate were increased 3.4- and 20-fold in diabetic rats
compared with those in control rats. Whereas aceto-
acetate concentration was further increased by pra-
zosin treatment (by 55% vs. the untreated diabetic
group), b-hydroxybutyrate concentration was 38%
lower in prazosin-treated diabetic rats compared
with the untreated diabetic group. Glutamate con-
centration was increased by 26% by diabetes, and
this increase was prevented by prazosin treatment.
Ammonia concentrations were similar in diabetic
rats treated with or without prazosin. a-Ketoglutarate
concentrations were similar in control and diabetic
rats and were increased by 27% in prazosin-treated
diabetic rats vs. the untreated diabetic group. Pyru-
vate concentration was increased by 23% in diabetic
rats vs. controls and this increase was not prevented
by prazosin treatment. Lactate concentration was
increased by 58% in diabetic rats compared with
controls and tended to decrease with prazosin treat-
ment, although the difference with the untreated
diabetic group did not achieve statistical signifi-
cance.
Free NAD1:NADH ratios in nerve mitochondrial
cristae and matrix (Fig. 3A) as well as cytosol (Fig.
3B) were similar in control rats treated with or
without prazosin. The three ratios were decreased by
77%, 32%, and 27% in diabetic rats compared with
those in control rats (P,0.01 for all three ratios).
Diabetes-induced NAD-redox changes in mitochon-
drial cristae were partially prevented by prazosin
treatment. Free NAD1:NADH ratio in prazosin-
treated diabetic group was 150% higher than in the
Figure 1. Sciatic NBF (A), systemic BP (B), and endoneurial
VC (C) in control and diabetic rats treated with or without
prazosin (mean 6sd, n512–15).
Figure 2. Sciatic MNCV in
control and diabetic rats
treated with or without pra-
zosin (mean 6sd, n58).
TABLE 1. Initial and final body weights (g) and blood glucose concentrations (mM)a
Body weight Blood glucose concentration
Initial Final Initial Final
Control (34) 250 6 19 390 6 17 3.7 6 0.5 2.9 6 0.5
Control 1 prazosin (10) 269 6 20 384 6 18 4.0 6 0.5 3.2 6 0.3
Diabetic (35) 242 6 21 269 6 51** 13.4 6 1.2** 18.9 6 3.3**
Diabetic 1 prazosin (32) 253 6 19 256 6 39** 14.0 6 1.1** 19.6 6 2.3**
a The number of observations is indicated in parentheses. ** Significantly different compared to those in controls (P , 0.01).
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untreated diabetic group (P,0.01) and 44% lower
than in nondiabetic controls (P,0.01). A diabetes-
induced decrease in free NAD1:NADH ratios in
mitochondrial matrix and cytosol was prevented by
prazosin treatment (P,0.01 and , 0.05 vs. the
untreated diabetic group). Free NAD1:NADH ratios
in either mitochondrial matrix or cytosol were not
different between diabetic rats treated with prazosin
and nondiabetic controls.
Nerve ATP concentrations were similar in control
and diabetic groups treated with and without prazo-
sin (Table 3). PCr concentrations and PCr:Cr ratios
were not different in control rats treated with or
without prazosin. PCr concentrations and PCr:Cr
ratios were reduced in diabetic rats (by 13% and
22.5% vs. control group), and the decrease in both
parameters was prevented by prazosin treatment. Cr
concentrations were not different among control
and diabetic rats treated with and without prazosin.
Nerve glucose, sorbitol, and fructose concentra-
tions were 852%, 456%, and 175% higher in diabetic
rats compared with those in control rats (Table 4);
none of these parameters were affected by prazosin
treatment.
Nerve myo-inositol and taurine concentrations
(Fig. 4A) were reduced by 24% and 39% in diabetic
rats vs. controls (P,0.05 and , 0.01, respectively),
and depletion of either osmolyte was not prevented
by prazosin treatment. (Na/K)-ATP-ase activity (Fig.
4B) was 34% lower in diabetic rats compared with
the control group (P,0.01); this decrease was not
affected by prazosin treatment.
Nerve GSH concentration (Fig. 5A) was decreased
by 29% in diabetic rats vs. controls (P,0.01), and
this decrease was not prevented by prazosin treat-
ment. Nerve MDA concentrations were similar in
control, diabetic untreated, and prazosin-treated di-
abetic rats (Fig. 5B). Nerve MDA plus 4-HA concen-
tration was increased by 40% in diabetic rats vs.
controls (P,0.05); this increase was not prevented
by prazosin treatment.
DISCUSSION
The diabetic state in humans is associated with
marked abnormalities of microvascular regulation
(49). Diabetes-induced decrease in NBF in the
present study is consistent with other reports for
both exposed (1–6, 8–12, 50–52) and unexposed
(53, 54) diabetic nerve. Prevention of both diabetes-
induced neurovascular dysfunction and MNCV defi-
cit by a1-adrenoceptor antagonist prazosin is consis-
tent with previous studies by Cameron’s group with
prazosin (55), another a1-adrenoceptor antagonist,
doxazosin (13), and vasodilators such as the b2-
adrenoreceptor agonist salbutamol (13), angioten-
sin-converting enzyme inhibitor lisinopril (17), and
the calcium antagonist nifedipine (18).
A decrease in free NAD1:NADH ratios in nerve
mitochondrial cristae and matrix in diabetes as well
as partial (cristae) or complete (matrix) prevention
of the NAD-redox imbalances by the vasodilator
therapy is indicative of diabetes-induced endoneur-
ial hypoxia. The effect of prazosin on both ratios is
specific for diabetic animals and therefore is not due
to some unidentified intrinsic properties of the
compound, not related to its vasodilator activity. The
findings of decreased free mitochondrial NAD1:
NADH ratios in the diabetic peripheral nerve are
consistent with a diabetes-induced decrease in NBF
and peripheral nerve oxygen tensions (10, 56, 57).
Figure 3. Free NAD1:NADH ratios in sciatic nerve mitochon-
drial cristae and matrix (A) and cytosol (B) in control and
diabetic rats treated with or without prazosin (mean 6sd,
n57–18).
TABLE 2. Steady-state concentrations (mmol/g wet weight) of metabolites of b-hydroxybutyrate dehydrogenase, glutamate dehydrogenase,
and lactate dehydrogenase systems in control and diabetic rats treated with or without prazosin (n 5 7-20)
Control Control 1 prazosin Diabetic Diabetic 1 prazosin
Acetoacetate 0.088 6 0.025 0.079 6 0.020 0.389 6 0.060** 0.602 6 0.069**,##
b-Hydroxybutyrate 0.061 6 0.021 0.064 6 0.013 1.282 6 0.163** 0.801 6 0.065**,##
Glutamate 1.75 6 0.19 1.78 6 0.36 2.20 6 0.27** 1.61 6 0.12##
a-Ketoglutarate 0.163 6 0.016 0.181 6 0.017 0.154 6 0.024 0.195 6 0.016**,##
Ammonia 1.06 6 0.16 0.90 6 0.18 0.95 6 0.14 0.98 6 0.16
Pyruvate 0.188 6 0.031 0.163 6 0.023 0.232 6 0.038* 0.245 6 0.042**
Lactate 1.787 6 0.399 1.50 6 0.140 2.82 6 0.396** 2.503 6 0.396**
*,** Significantly different compared to those in controls (P , 0.05 and , 0.01, respectively); ## significantly different compared to those
in untreated diabetics (P , 0.01).
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Furthermore, the assessment of free mitochondrial
NAD1:NADH ratios in our study has been per-
formed in femoral segments of the sciatic nerve
sampled within 30 s after euthanasia, i.e., without
prolonged surgical exposure of the nerve. Thus, our
results argue against the premise that the findings of
decreased NBF and oxygenation in the diabetic
nerve is an artifact of nerve surgical exposure during
NBF measurements by hydrogen clearance or laser
Doppler procedures (21), and confirm that the
diabetic peripheral nerve is truly hypoxic. The find-
ings of a 77% decrease in free NAD1:NADH ratio in
the mitochondrial cristae of the diabetic nerve vs.
;40–50% decrease of nerve oxygen tensions in
other reports (10, 56, 57), as well as of incomplete
prevention of the NAD-redox changes despite pres-
ervation of normal VC in prazosin-treated diabetic
rats, indicate that, in addition to decreased NBF/
endoneurial hypoxia, other factors affect mitochon-
drial oxidative capacity of the diabetic nerve. These
may include osmotic stress with resulting distur-
bances in Ca21 homeostasis and oxidative stress
leading to inhibition of respiratory chain enzymes,
e.g., cytochrome C oxidase (58). The role for these
nonvascular mechanisms affecting mitochondrial ox-
idative capacity in diabetes-induced nerve conduc-
tion slowing is minor as MNCV deficit was prevented
by prazosin treatment. Despite a decrease of nerve
mitochondrial oxidative capacity to about half that
of normal, a free NAD1:NADH ratio in mitochon-
drial matrix of prazosin-treated diabetic rats was
preserved in the range of nondiabetic animals. This
ratio controls the activity of tricarboxylic acid cycle,
the major source of energy in aerobic tissues. There-
fore, it is not surprising that PCr levels as well as the
PCr/Cr ratio, the most sensitive parameter of the
peripheral nerve energy state (59, 60) in the diabetic
rats treated with prazosin, are in the range of those
in controls. The responsiveness of nerve PCr concen-
tration to vasodilator treatment in our experiments
is consistent with reports (61, 62) of the sensitivity of
this parameter to changes in perfusion/oxygenation.
Two aforementioned studies (61, 62) as well as our
findings suggest that of a variety of metabolic param-
eters, nerve energy state correlates best with MNC.
Decrease in free cytosolic NAD1:NADH ratio in
the diabetic nerve is also prevented by the vasodila-
tor treatment despite the absence of any effect of
prazosin on the sorbitol pathway intermediates.
Therefore, our findings do not support the concept
of ‘diabetic pseudohypoxia’, suggesting that diabe-
tes-induced cytosolic NAD-redox imbalances are due
to increased oxidation of sorbitol to fructose, cou-
pled to reduction of NAD to NADH, by sorbitol
dehydrogenase (SDH) (63). The conclusion of the
independence of the shift toward a more reduced
state of free cytosolic NAD-couple from increased
SDH activity is supported by another study from our
laboratory (37). We have found that an SDH inhib-
itor (SDI) at a dose resulting in 91% inhibition of the
increased flux through SDH failed to prevent either
cytosolic or mitochondrial NAD-redox imbalances in
the diabetic nerve. Taking into consideration, that
mitochondrial and cytosolic pools of nicotinamide
adenine dinucleotides are linked through dicarboxy-
late carriers and that the peripheral nerve strongly
depends on oxidative (aerobic) metabolism (64), it
is reasonable to suggest that diabetes-associated cy-
tosolic NAD-redox imbalances have a mitochondrial
origin, i.e., reflect a metabolic response of the cyto-
plasm to endoneurial hypoxia developing due to
decreased NBF.
Although advanced glycation end-products accu-
mulate in the peripheral nerve at a later stage of
TABLE 3. Nerve energy status in control and diabetic rats treated with or without prazosin (n 5 10-20)a
Control Control 1 prazosin Diabetic Diabetic 1 prazosin
ATP 1.103 6 0.309 0.979 6 0.244 1.150 6 0.364 0.982 6 0.158
PCr 2.697 6 0.373 2.705 6 0.405 2.359 6 0.416* 2.574 6 0.418#
Cr 3.951 6 0.639 3.365 6 0.632 4.339 6 0.559 3.854 6 0.958
PCr/Cr 0.703 6 0.092 0.818 6 0.145 0.545 6 0.084** 0.723 6 0.109##
a Concentrations of ATP, PCr, and Cr are expressed in mmol/g wet weight. *,** Significantly different compared with those in controls (P ,
0.05 and , 0.01, respectively); #,## significantly different compared with those in untreated diabetics (P , 0.05 and , 0.01, respectively).
Abbreviations: PCr, phosphocreatine; Cr, creatine.
TABLE 4. Nerve glucose, sorbitol, and fructose concentrations (mmol/g wet weight)
in control and diabetic rats treated with or without prazosin (n 5 7-9)
Control Diabetic Diabetic 1 prazosin
Glucose 1.88 6 0.44 17.89 6 6.80** 19.24 6 3.51**
Sorbitol 0.329 6 0.079 1.83 6 0.38** 2.36 6 0.55**
Fructose 2.31 6 0.72 6.36 6 2.07** 6.51 6 1.30**
** Significantly different compared to those in controls (P , 0.01).
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PDN (65), the Amadori products recently implicated
in the pathogenesis of diabetic complications (66)
form in early diabetes. The fact that the vasodilator
treatment prevented MNCV deficit without affecting
the concentrations of two most abundant glycation
agents, glucose and fructose (67), suggests that non-
enzymatic glycation of neural tissue macromolecules
is not implicated in MNC slowing in short-term
diabetes. This assumption is consistent with the
absence of increased levels of methylglyoxal, the
a-dicarbonyl compound that reacts with proteins
with formation of imidazolium cross-linking AGEs
(68) in the sciatic nerve at the early stage of PDN
(69). There are no reports of the presence of an-
other potent glycation agent, 3-deoxyglucosone (70,
71), in the neural tissues. Furthermore, this reactive
dicarbonyl is formed by nonenzymatic degradation
of glucose-derived Amadori products (70–72) and,
in some tissues (73), by nonenzymatic decomposi-
tion of sorbitol pathway-originated fructose 3-phos-
phate. Therefore, it is inconceivable that 3-deoxyglu-
cosone levels, if present, are modulated by the agent
(prazosin) that does not affect either glucose or
fructose levels in the diabetic nerve. The blockade of
a preventive effect of aminoguanidine on diabetes-
induced nerve conduction slowing by cotreatment
with the nitric oxide synthase inhibitor NG-nitro-L-
arginine (16) is consistent with the important role of
AGE in vasa nervorum, but not neural tissue, in NCV
deficit in early diabetes.
In a similar fashion, prevention of diabetes-in-
duced MNCV deficit despite the absence of any
effect of prazosin on nerve sorbitol levels implies that
sorbitol accumulation is not a major culprit in the
early phase of PDN. This conclusion is consistent
with observations of others. In particular, Cameron
et al. (11) did not find any MNC and sensory NC
slowing in nondiabetic rats treated with a SDI that
increased nerve sorbitol accumulation to the level
found in the diabetic rats. Ng et al. (74) reported
similar MNCV deficits in the diabetic mice with
normal SDH levels and SDH-deficient diabetic mice
with 8.9-fold higher nerve sorbitol concentration.
Song et al. (75) found no difference in MNCV
deficits between diabetic mice, overexpressing al-
dose reductase in Schwann cells, and nontransgenic
diabetic mice. However, despite these and our find-
ings, one should keep in mind that nerve sorbitol
accumulation could be of much greater importance
in advanced PDN. Dyck et al. (76) have reported that
nerve sorbitol content in the diabetic patients is
inversely related to the number of myelinated fibers.
Of particular interest is the study by Schmidt et al.
(77), who found a dramatic increase in ileal mesen-
teric nerve axonal dystrophy with SDH inhibition by
the dose of SDI not affecting NBF in the diabetic
model of lesser duration (11). Long-term experi-
ments with a SDI are needed to estimate whether
similar axonopathy will develop in the peripheral
nerve in response to persistent excessive nerve sor-
bitol accumulation.
The role for myo-inositol depletion in diabetes-
induced NC deficit remains controversial. Two
groups (78–80) have reported amelioration of
MNCV deficit in the diabetic rats fed 1% myo-inositol
diet or receiving 500 mg/kg per day of myo-inositol in
the drinking water, whereas others did not find any
effect of dietary myo-inositol supplementation on
either neurovascular dysfunction or nerve conduc-
tion deficits in the intervention study with a ;2.5-
fold higher dose of myo-inositol (81). It is unclear
whether different observations regarding efficacy of
myo-inositol on diabetes-induced NC slowing are due
to the difference in dose and whether 2.5% myo-
inositol supplementation (81) is associated with ad-
verse side effects, preventing preservation of MNCV
and not characteristic of the 1% diet. In addition,
clinical studies have revealed the absence of myo-
inositol depletion in the diabetic patients (76, 82,
83). Sundkvist et al. (83), but not Dyck et al. (76),
found an association between nerve myo-inositol de-
pletion and the presence of PDN. The present study,
demonstrating that MNCV deficit is prevented by
prazosin despite the absence of any effect of the
Figure 5. Sciatic nerve GSH (A) and MDA and MDA plus
4-HA (B) concentrations in control and diabetic rats treated
with or without prazosin (mean 6sd, n512–15).
Figure 4. Sciatic nerve myo-inositol and taurine concentra-
tions (A) and (Na/K)-ATP-ase activities (B) in control and
diabetic rats treated with or without prazosin (mean 6sd,
n57–8).
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vasodilator on nerve myo-inositol and taurine concen-
trations, indicates that preservation the two os-
molytes in the neural tissue is not essential for
prevention of NC slowing in short-term diabetes.
Taking into consideration that taurine prevents dia-
betes-induced changes in NBF (84) and that Na1/
taurine cotransporter is localized in vasa nervorum
(85), it is reasonable to suggest that the preventive
effect of taurine on MNC and sensory NC in diabetes
(84) is of vascular origin. The latter would be con-
sistent with vasodilator properties of taurine (86)
and its inhibitory effect on protein kinase C (87).
Despite the lack of prevention of diabetes-induced
decrease in (Na/K)-ATP-ase activity, preservation of
MNCV by prazosin treatment indicates that down-
regulation of (Na/K)-ATP-ase is not implicated in
early MNCV deficit in diabetes. This conclusion is
supported by other studies demonstrating the ab-
sence of any up-regulation of this enzyme by vasodi-
lators that effectively prevent MNC slowing (55) or,
conversely, an up-regulation of (Na/K)-ATP-ase
without any improvement of MNCV by NGF (M. J.
Stevens, unpublished results) or DL-a-lipoic acid
(88). The role for (Na/K)-ATP-ase in advanced PDN
remains unclear.
One of the most interesting findings of the present
study is an apparent dissociation between accumula-
tion of lipid peroxidation products in the neural
tissue and early MNCV deficit in diabetes despite
reports of prevention (1, 2, 36) and reversal (57) of
diabetes-induced changes in NC by different antioxi-
dants and metal chelators. These observations and
our findings demonstrating that prazosin preserves
MNCV without preventing diabetes-induced lipid
peroxidation in the neural tissue lead to the conclu-
sion that effects of antioxidants and metal chelators
on NC in short-term diabetes are mediated through
vascular mechanisms. Preservation of GSH and pre-
vention of lipid peroxidation in nerve vasculature is
probably more important in short-term diabetes
than preservation of nerve GSH concentration and
arrest of lipid peroxidation in the neural tissue (1,
89, 90). This conclusion is consistent with report of
Cameron and Cotter (91) indicating that the bene-
ficial effect of the free radical scavenger BM 15.0639
on diabetes-related NCV deficit is largely abolished
by cotreatment with nitric oxide synthase inhibitor.
However, it is important to remember that oxidative
stress is implicated in impaired neurotropism (36)
and mitochondrial dysfunction (92), associated with
Schwann cell injury (93, 94), and is a powerful
activator of three subfamilies of mitogen-activated
protein kinases (MAPKs), i.e., stress-activated pro-
tein kinase/c-Jun-terminal kinases, the extracellu-
larly responsive kinases and p38-MAPK (95–97), glu-
cose transducers for diabetic complications (98),
and particularly axonopathy (99). Both Schwann cell
injury and axonopathy, developing gradually and
becoming manifested in long-standing diabetes, ex-
acerbate nerve functional deficits acquired in the
initial phase of PDR. Thus, oxidative stress, acting
through both vascular and nonvascular mechanisms,
contributes to both onset and progression of PDR. In
addition, oxidative injury affects neurotransmission
(100) contributing to diabetes-induced endothelial
dysfunction (101).
In conclusion, a decrease in NBF with resulting
endoneurial hypoxia is a key mechanism of MNC
slowing in the early phase of PDN. The question
regarding the importance of vascular vs. nonvascular
mechanisms in advanced PDN remains open. Long-
term experiments with vasodilators are needed to
establish whether preservation of NBF is sufficient
for prevention of functional and morphological ab-
normalities in the peripheral nerve in long-standing
diabetes. On the other hand, chronic experiments
with coadministration of nitric oxide synthase inhib-
itor and one of the following agents, i.e., aldose
reductase inhibitors, myo-inositol, taurine, antioxi-
dants, IGF or NGF, or SDI administration, can clarify
the role for metabolic imbalances and enhanced
oxidative stress in the neural tissue as well as im-
paired neurotrophic support in advanced PDN.
The authors are grateful to Drs. Norman E. Cameron and
Mary A. Cotter for valuable help in setting the measurements
of endoneurial nutritive blood flow and the protocol of
prazosin administration.
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